Drugs / CD207 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05477446 | Oct 2022 → Jun 2025 | Langerhans cell histiocytosis | Beijing Friendship Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD207 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05477446 ↗ |
| Modality | Cell therapy | “CD207 targeted CAR-T cell therapy” NCT05477446 ↗ |
| Route | Intravenous | “Single dose of CD207 CAR-T cells administered IV” NCT05477446 ↗ |
| Target | CD207 | “CD207 is expressed on the membrane surface of langerhans cells，and it is an ideal target for CAR-T.” NCT05477446 ↗ |